	US 12,280,034 B2
	Sigma-1 receptor agonist systolic blood pressure therapy
Christopher U. Missling, New York, NY (US)
Assigned to Anavex Life Sciences Corp., New York, NY (US)
Filed by ANAVEX LIFE SCIENCES CORP., New York, NY (US)
Filed on Nov. 14, 2022, as Appl. No. 17/986,488.
Application 17/986,488 is a continuation of application No. 16/767,990, granted, now 11,622,955, previously published as PCT/US2018/062853, filed on Nov. 28, 2018.
Claims priority of provisional application 62/591,248, filed on Nov. 28, 2017.
Prior Publication US 2023/0071766 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/341 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/341 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01)]

21 Claims

1. A method of treating hypertension comprising administering to a subject in need thereof a therapeutically effective amount of a therapeutic agent selected from tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanmethanamine, a salt thereof, and any combination thereof.